GlassScriptPhysician profile
Evangelos Biscotakis
NPI 1487835138
$4,284.40
in general payments reported to CMS, 2019-2025
34 companies · $2,569 in 2025
The $2,569 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $25.84 · 2021: $174 · 2022: $172 · 2023: $81.05 · 2024: $1,059 · 2025: $2,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624 · Education: $70.81 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.05 |
| Education | $70.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $569.80 | 2024-2025 | Eterna, Proclaim |
| Corcept Therapeutics | $532.42 | 2024-2025 | Korlym |
| Novo Nordisk INC | $414.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $388.29 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $386.49 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $249.31 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Spinal Simplicity, LLC | $180.85 | 2025 | Ha Minuteman G3-R |
| Pfizer INC. | $174.90 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $139.45 | 2025 | Rexulti |
| Lundbeck LLC | $138.89 | 2024-2025 | Rexulti |
| Eisai INC. | $126.16 | 2025 | |
| Genzyme Corporation | $122.90 | 2021 | |
| Axsome Therapeutics, INC. | $120.24 | 2025 | Symbravo |
| Mannkind Corporation | $118.80 | 2022 | |
| Nestle Healthcare Nutrition INC. | $99.30 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.78 | 2024-2025 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.81 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $48.67 | 2025 | |
| Exact Sciences Corporation | $39.88 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $38.35 | 2021-2022 | |
| Madrigal Pharmaceuticals | $30.04 | 2025 | Rezdiffra |
| Inspire Medical Systems, INC. | $26.99 | 2025 | Inspire |
| Dexcom, INC. | $23.75 | 2025 | Dexcom G6 Transmitter |
| C2n Diagnostics, LLC | $22.30 | 2025 | Precivityad2 |
| Cleerly, INC. | $21.44 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $21.41 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biogen, INC. | $21.23 | 2025 | Skyclarys |
| Rgh Enterprises LLC | $20.85 | 2025 | |
| Baxter Healthcare | $19.90 | 2024 | Biopharma Sol - Contract Manuf |
| Antares Pharma, INC. | $18.85 | 2025 | Xyosted |
| Lucid Diagnostics INC. | $16.51 | 2025 | |
| Philips North America LLC | $15.13 | 2024 | (Ck7) Extended Holter |
| Medicure Pharma INC. | $15.04 | 2024 | Zypitamag |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evangelos Biscotakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.